53 completed, 15 recruiting, 14 terminated, 7 unknown. 95 Phase 3, 12 Phase 2.
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-23 | 2026-11-10 |
| Clinical Investigation of Safety and Effectiveness for the enVVe® System envve system - Chronic Venous Insufficiency, CVI | Phase 2 / Phase 3 | Not yet recruiting | Hancock Jaffe Laboratiores, Inc | 220 | 2026-07-01 | 2026-05-27 |
| Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research Privosegtor, Methylprednisolone, Placebo - Optic Neuritis | Phase 3 | Recruiting | Oculis | 210 | 2026-05-28 | 2026-08-14 |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) Ixo-vec, Aflibercept - Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Recruiting | Adverum Biotechnologies, Inc. | 534 | 2026-03-16 | 2026-09-24 |
| A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene Fampridine 10 mg prolonged-release tablet (per os), Placebo (tablets per os) - Spinocerebellar Ataxia 27B (SCA27B) | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2025-10-21 | 2025-12-10 |
| OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity 0.75% Phentolamine Ophthalmic Solution, Placebo - Vision Loss Night, Vision Disorders | Phase 3 | Recruiting | Opus Genetics, Inc | 580 | 2025-09-02 | 2026-10-14 |
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration Ixo-vec, Aflibercept - Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Active not recruiting | Adverum Biotechnologies, Inc. | 311 | 2025-02-28 | 2026-05-22 |
| Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age Vivid Vision, Luminopia, Optical Correction - Amblyopia | Phase 3 | Recruiting | Jaeb Center for Health Research | 252 | 2024-10-22 | 2026-11-02 |
| Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age Luminopia, Eye Patch - Amblyopia | Phase 3 | Recruiting | Jaeb Center for Health Research | 238 | 2024-07-11 | 2026-11-02 |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) Tarcocimab, Sham injection - Diabetic Retinopathy | Phase 3 | Completed | Kodiak Sciences Inc | 255 | 2024-05-01 | 2026-05-13 |
| Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy Faricimab, fluocinolone acetonide - Radiation Retinopathy, Visual Impairment | Phase 3 | Recruiting | Jaeb Center for Health Research | 600 | 2023-11-21 | 2026-10-23 |
| Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel GIE Medical ProTractX3 TTS DCB, Control - Bowel; Stricture | Phase 3 | Recruiting | GIE Medical | 171 | 2023-11-01 | 2025-06-25 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| Alcohol Use Disorder and Cannabidiol Cannabidiol, Placebo - Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 180 | 2023-04-30 | 2026-06-15 |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Rimegepant, Placebo - Migraine | Phase 3 | Recruiting | Pfizer | 640 | 2022-02-28 | 2026-10-14 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
Showing 20 of 95. Sign in to see all of them.
Eye Diseases (23) · Amblyopia (20) · Retinal Diseases (18) · Macular Edema (17) · Blindness (16) · Macular Degeneration (12) · Retinal Vein Occlusion (11) · Retinal Degeneration (10) · Diabetic Retinopathy (8) · Migraine Disorders (8) · Photophobia (8) · Diabetes Mellitus (7) · Hyperacusis (7) · Nausea (7)
Pathological Conditions, Signs and Symptoms (95) · Signs and Symptoms (95) · Neurologic Manifestations (92) · Sensation Disorders (92) · Nervous System Diseases (91) · Eye Diseases (72) · Brain Diseases (32) · Central Nervous System Diseases (32) · Retinal Diseases (27) · Retinal Degeneration (26) · Cardiovascular Diseases (21) · Vascular Diseases (20) · Eye Diseases, Hereditary (16) · Macular Degeneration (16)
Ranibizumab (15) · aflibercept (14) · salicylhydroxamic acid (12) · Atropine (7) · brolucizumab (7) · tasimelteon (4) · Eyeglasses (3) · Lasers (3) · rimegepant sulfate (3) · Acetazolamide (2) · Aspirin (2) · Dexamethasone (2) · Intravitreal Injections (2) · 4-Aminopyridine (1) · Acetaminophen (1)
Jaeb Center for Health Research (19) · Novartis Pharmaceuticals (18) · Kodiak Sciences Inc (7) · Pfizer (6) · National Eye Institute (NEI) (4) · Vanda Pharmaceuticals (4) · Laboratoires Thea (3) · Adverum Biotechnologies, Inc. (2) · Bayer (2) · Genentech, Inc. (2) · Nacuity Pharmaceuticals, Inc. (2) · ProQR Therapeutics (2) · Thomas Jefferson University (2) · Alcon Research (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (60) · Germany (20) · France (19) · Canada (17) · Spain (17) · United Kingdom (17) · Italy (14) · Czechia (13) · Poland (12) · Netherlands (11) · Hungary (10) · Puerto Rico (10) · Slovakia (9) · Australia (8) · Israel (8)
Pablo Velazquez-Martin, MD (7) · David K. Wallace, M.D. (4) · Adam Turpcu, PhD (2) · Jason Ehrlich, M.D., Ph.D. (2) · Michael Wall, MD (2) · Michael X Repka, M.D. (2) · Mitchell M. Scheiman, O.D. (2) · Richard W. Hertle, M.D. (2) · Susan A. Cotter, O.D. (2)
PMID 20451898, PMID 22108357, PMID 22965590, PMID 23706949, PMID 24768239, PMID 25148789, PMID 26050541, PMID 26452713, PMID 26466871, PMID 26584450, PMID 26992841, PMID 27234930, PMID 29752001, PMID 30419298, PMID 31047350, PMID 31047503, PMID 31668888, PMID 36774994, PMID 37585454, PMID 39680390, PMID 10654946, PMID 16751032, PMID 16751033, PMID 17679633, PMID 18789533, PMID 19064841, PMID 19139333, PMID 19541265, PMID 20126486, PMID 20163869, PMID 20413522, PMID 21419678, PMID 21746992, PMID 22633344, PMID 23084240, PMID 23528439, PMID 23563444, PMID 23755872, PMID 24084500, PMID 24756302, PMID 24756514, PMID 24781936, PMID 24789375, PMID 25016366, PMID 25107900, PMID 25370510, PMID 25370513, PMID 25439429, PMID 25676904, PMID 25727586
U10EY011751 (14), 2018 (3), 2019 (3), 2UG1EY011751 (3), 1UG1EY033293 (1), M01RR000054 (1), M01RR000070 (1), R01AA029606 (1), R01MH061331 (1), U10EY017281 (1), U10EY017387 (1), U10EY025990 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1)